Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy
Background: WHO developed a global strategy to eliminate hepatitis B by 2030 and set target to treat 80% of people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment. As a first step to achieve this goal, it is essential to conduct a situation analysis that is fundamental to designing national hepatitis plans. We therefore estimated the prevalence of chronic HBV infection, and described the existing infrastructure for HBV diagnosis in Madagascar. Methods: We conducted a stratified multi-stage serosurvey of hepatitis B surface antigen (HBsAg) in adults aged ≥18 years using 28 sentinel surveillance sites located throughout the country. We obtained the list of facilities performing HBV testing from the Ministry of Health, and contacted the person responsible at each facility. Results A total of 1778 adults were recruited from the 28 study areas. The overall weighted seroprevalence of HBsAg was 6.9% (95% CI: 5.6–8.6). Populations with a low socio-economic status and those living in rural areas had a significantly higher seroprevalence of HBsAg. The ratio of facilities equipped to perform HBsAg tests per 100,000 inhabitants was 1.02 in the capital city of Antananarivo and 0.21 outside the capital. There were no facilities with the capacity to perform HBV DNA testing or transient elastography to measure liver fibrosis. There are only five hepatologists in Madagascar. Conclusion: Madagascar has a high-intermediate level of endemicity for HBV infection with a severely limited capacity for its diagnosis and treatment. Higher HBsAg prevalence in rural or underprivileged populations underlines the importance of a public health approach to decentralize the management of chronic HBV carriers in Madagascar by using simple and low-cost diagnostic tools.
id |
dig-cirad-fr-585166 |
---|---|
record_format |
koha |
institution |
CIRAD FR |
collection |
DSpace |
country |
Francia |
countrycode |
FR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-cirad-fr |
tag |
biblioteca |
region |
Europa del Oeste |
libraryname |
Biblioteca del CIRAD Francia |
language |
eng |
topic |
000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 http://aims.fao.org/aos/agrovoc/c_4510 000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 http://aims.fao.org/aos/agrovoc/c_4510 |
spellingShingle |
000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 http://aims.fao.org/aos/agrovoc/c_4510 000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 http://aims.fao.org/aos/agrovoc/c_4510 Andriamandimby, Soa Fy Olive, Marie-Marie Shimakawa, Yusuke Rakotomanana, Fanjasoa Razanajatovo, Iony Manitra Andrianinarivomanana, Tsarasoa Malala Ravalohery, Jean-Pierre Andriamamonjy, Seta Rogier, Christophe Héraud, Jean Michel Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
description |
Background: WHO developed a global strategy to eliminate hepatitis B by 2030 and set target to treat 80% of people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment. As a first step to achieve this goal, it is essential to conduct a situation analysis that is fundamental to designing national hepatitis plans. We therefore estimated the prevalence of chronic HBV infection, and described the existing infrastructure for HBV diagnosis in Madagascar. Methods: We conducted a stratified multi-stage serosurvey of hepatitis B surface antigen (HBsAg) in adults aged ≥18 years using 28 sentinel surveillance sites located throughout the country. We obtained the list of facilities performing HBV testing from the Ministry of Health, and contacted the person responsible at each facility. Results A total of 1778 adults were recruited from the 28 study areas. The overall weighted seroprevalence of HBsAg was 6.9% (95% CI: 5.6–8.6). Populations with a low socio-economic status and those living in rural areas had a significantly higher seroprevalence of HBsAg. The ratio of facilities equipped to perform HBsAg tests per 100,000 inhabitants was 1.02 in the capital city of Antananarivo and 0.21 outside the capital. There were no facilities with the capacity to perform HBV DNA testing or transient elastography to measure liver fibrosis. There are only five hepatologists in Madagascar. Conclusion: Madagascar has a high-intermediate level of endemicity for HBV infection with a severely limited capacity for its diagnosis and treatment. Higher HBsAg prevalence in rural or underprivileged populations underlines the importance of a public health approach to decentralize the management of chronic HBV carriers in Madagascar by using simple and low-cost diagnostic tools. |
format |
article |
topic_facet |
000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 http://aims.fao.org/aos/agrovoc/c_4510 |
author |
Andriamandimby, Soa Fy Olive, Marie-Marie Shimakawa, Yusuke Rakotomanana, Fanjasoa Razanajatovo, Iony Manitra Andrianinarivomanana, Tsarasoa Malala Ravalohery, Jean-Pierre Andriamamonjy, Seta Rogier, Christophe Héraud, Jean Michel |
author_facet |
Andriamandimby, Soa Fy Olive, Marie-Marie Shimakawa, Yusuke Rakotomanana, Fanjasoa Razanajatovo, Iony Manitra Andrianinarivomanana, Tsarasoa Malala Ravalohery, Jean-Pierre Andriamamonjy, Seta Rogier, Christophe Héraud, Jean Michel |
author_sort |
Andriamandimby, Soa Fy |
title |
Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
title_short |
Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
title_full |
Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
title_fullStr |
Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
title_full_unstemmed |
Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy |
title_sort |
prevalence of chronic hepatitis b virus infection and infrastructure for its diagnosis in madagascar: implication for the who's elimination strategy |
url |
http://agritrop.cirad.fr/585166/ http://agritrop.cirad.fr/585166/1/HEVB_Madgascar_MMO2017.pdf |
work_keys_str_mv |
AT andriamandimbysoafy prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT olivemariemarie prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT shimakawayusuke prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT rakotomananafanjasoa prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT razanajatovoionymanitra prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT andrianinarivomananatsarasoamalala prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT ravaloheryjeanpierre prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT andriamamonjyseta prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT rogierchristophe prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy AT heraudjeanmichel prevalenceofchronichepatitisbvirusinfectionandinfrastructureforitsdiagnosisinmadagascarimplicationforthewhoseliminationstrategy |
_version_ |
1792499328347013120 |
spelling |
dig-cirad-fr-5851662024-01-29T00:28:19Z http://agritrop.cirad.fr/585166/ http://agritrop.cirad.fr/585166/ Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy. Andriamandimby Soa Fy, Olive Marie-Marie, Shimakawa Yusuke, Rakotomanana Fanjasoa, Razanajatovo Iony Manitra, Andrianinarivomanana Tsarasoa Malala, Ravalohery Jean-Pierre, Andriamamonjy Seta, Rogier Christophe, Héraud Jean Michel. 2017. BMC Public Health, 17:636, 9 p.https://doi.org/10.1186/s12889-017-4630-z <https://doi.org/10.1186/s12889-017-4630-z> Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: Implication for the WHO's elimination strategy Andriamandimby, Soa Fy Olive, Marie-Marie Shimakawa, Yusuke Rakotomanana, Fanjasoa Razanajatovo, Iony Manitra Andrianinarivomanana, Tsarasoa Malala Ravalohery, Jean-Pierre Andriamamonjy, Seta Rogier, Christophe Héraud, Jean Michel eng 2017 BMC Public Health 000 - Autres thèmes L73 - Maladies des animaux hépatite Enquête pathologique genre humain morbidité éradication des maladies technique immunologique sérologie niveau de vie population rurale analyse du risque santé publique infection http://aims.fao.org/aos/agrovoc/c_11527 http://aims.fao.org/aos/agrovoc/c_28665 http://aims.fao.org/aos/agrovoc/c_4586 http://aims.fao.org/aos/agrovoc/c_4936 http://aims.fao.org/aos/agrovoc/c_25233 http://aims.fao.org/aos/agrovoc/c_3807 http://aims.fao.org/aos/agrovoc/c_27081 http://aims.fao.org/aos/agrovoc/c_4400 http://aims.fao.org/aos/agrovoc/c_6705 http://aims.fao.org/aos/agrovoc/c_37936 http://aims.fao.org/aos/agrovoc/c_6349 http://aims.fao.org/aos/agrovoc/c_3852 Madagascar http://aims.fao.org/aos/agrovoc/c_4510 Background: WHO developed a global strategy to eliminate hepatitis B by 2030 and set target to treat 80% of people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment. As a first step to achieve this goal, it is essential to conduct a situation analysis that is fundamental to designing national hepatitis plans. We therefore estimated the prevalence of chronic HBV infection, and described the existing infrastructure for HBV diagnosis in Madagascar. Methods: We conducted a stratified multi-stage serosurvey of hepatitis B surface antigen (HBsAg) in adults aged ≥18 years using 28 sentinel surveillance sites located throughout the country. We obtained the list of facilities performing HBV testing from the Ministry of Health, and contacted the person responsible at each facility. Results A total of 1778 adults were recruited from the 28 study areas. The overall weighted seroprevalence of HBsAg was 6.9% (95% CI: 5.6–8.6). Populations with a low socio-economic status and those living in rural areas had a significantly higher seroprevalence of HBsAg. The ratio of facilities equipped to perform HBsAg tests per 100,000 inhabitants was 1.02 in the capital city of Antananarivo and 0.21 outside the capital. There were no facilities with the capacity to perform HBV DNA testing or transient elastography to measure liver fibrosis. There are only five hepatologists in Madagascar. Conclusion: Madagascar has a high-intermediate level of endemicity for HBV infection with a severely limited capacity for its diagnosis and treatment. Higher HBsAg prevalence in rural or underprivileged populations underlines the importance of a public health approach to decentralize the management of chronic HBV carriers in Madagascar by using simple and low-cost diagnostic tools. article info:eu-repo/semantics/article Journal Article info:eu-repo/semantics/publishedVersion http://agritrop.cirad.fr/585166/1/HEVB_Madgascar_MMO2017.pdf text Cirad license info:eu-repo/semantics/openAccess https://agritrop.cirad.fr/mention_legale.html https://doi.org/10.1186/s12889-017-4630-z 10.1186/s12889-017-4630-z info:eu-repo/semantics/altIdentifier/doi/10.1186/s12889-017-4630-z info:eu-repo/semantics/altIdentifier/purl/https://doi.org/10.1186/s12889-017-4630-z info:eu-repo/semantics/dataset/purl/https://figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_Prevalence_of_chronic_hepatitis_B_virus_infection_and_infrastructure_for_its_diagnosis_in_Madagascar_implication_for_the_WHO_s_elimination_strategy/5280532 |